全文获取类型
收费全文 | 129877篇 |
免费 | 8035篇 |
国内免费 | 1155篇 |
专业分类
耳鼻咽喉 | 2084篇 |
儿科学 | 1977篇 |
妇产科学 | 1960篇 |
基础医学 | 20750篇 |
口腔科学 | 3189篇 |
临床医学 | 12072篇 |
内科学 | 22872篇 |
皮肤病学 | 4240篇 |
神经病学 | 10608篇 |
特种医学 | 7487篇 |
外科学 | 17368篇 |
综合类 | 541篇 |
现状与发展 | 3篇 |
一般理论 | 29篇 |
预防医学 | 6715篇 |
眼科学 | 3322篇 |
药学 | 11848篇 |
中国医学 | 1526篇 |
肿瘤学 | 10476篇 |
出版年
2023年 | 689篇 |
2022年 | 722篇 |
2021年 | 4574篇 |
2020年 | 2245篇 |
2019年 | 3123篇 |
2018年 | 3872篇 |
2017年 | 3149篇 |
2016年 | 4155篇 |
2015年 | 5753篇 |
2014年 | 6792篇 |
2013年 | 7913篇 |
2012年 | 11796篇 |
2011年 | 11307篇 |
2010年 | 6515篇 |
2009年 | 5586篇 |
2008年 | 7853篇 |
2007年 | 7456篇 |
2006年 | 6741篇 |
2005年 | 6251篇 |
2004年 | 5408篇 |
2003年 | 4755篇 |
2002年 | 4076篇 |
2001年 | 3082篇 |
2000年 | 2831篇 |
1999年 | 2166篇 |
1998年 | 930篇 |
1997年 | 696篇 |
1996年 | 526篇 |
1995年 | 474篇 |
1994年 | 402篇 |
1993年 | 348篇 |
1992年 | 766篇 |
1991年 | 712篇 |
1990年 | 652篇 |
1989年 | 565篇 |
1988年 | 474篇 |
1987年 | 476篇 |
1986年 | 340篇 |
1985年 | 370篇 |
1984年 | 273篇 |
1983年 | 195篇 |
1982年 | 140篇 |
1981年 | 173篇 |
1980年 | 135篇 |
1979年 | 224篇 |
1978年 | 167篇 |
1976年 | 132篇 |
1975年 | 121篇 |
1974年 | 142篇 |
1973年 | 124篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
Sanne C. F. A. Huijberts Robin M. J. M. van Geel Emilie M. J. van Brummelen Frans L. Opdam Serena Marchetti Neeltje Steeghs Saskia Pulleman Bas Thijssen Hilde Rosing Kim Monkhorst Alwin D. R. Huitema Jos H. Beijnen Ren Bernards Jan H. M. Schellens 《Cancer chemotherapy and pharmacology》2020,85(5):917-930
KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo. In this phase I study, patients with advanced KRASm and PIK3CA wild-type colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer, were treated with combined lapatinib and trametinib to assess the recommended phase 2 regimen (RP2R). Patients received escalating doses of continuous or intermittent once daily (QD) orally administered lapatinib and trametinib, starting at 750 mg and 1 mg continuously, respectively. Thirty-four patients (16 CRC, 15 NSCLC, three pancreatic cancers) were enrolled across six dose levels and eight patients experienced dose-limiting toxicities, including grade 3 diarrhea (n = 2), rash (n = 2), nausea (n = 1), multiple grade 2 toxicities (n = 1), and aspartate aminotransferase elevation (n = 1), resulting in the inability to receive 75% of planned doses (n = 2) or treatment delay (n = 2). The RP2R with continuous dosing was 750 mg lapatinib QD plus 1 mg trametinib QD and with intermittent dosing 750 mg lapatinib QD and trametinib 1.5 mg QD 5 days on/2 days off. Regression of target lesions was seen in 6 of the 24 patients evaluable for response, with one confirmed partial response in NSCLC. Pharmacokinetic results were as expected. Lapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated. 相似文献
83.
Mohamed E. Salem J. Nicholas Bodor Alberto Puccini Joanne Xiu Richard M. Goldberg Axel Grothey W. Michael Korn Anthony F. Shields William M Worrilow Edward S. Kim Heinz-Josef Lenz John L. Marshall Michael J. Hall 《International journal of cancer. Journal international du cancer》2020,147(10):2948-2956
Microsatellite instability-high (MSI-H) and tumor mutational burden (TMB) are predictive biomarkers for immune-checkpoint inhibitors (ICIs). Still, the relationship between the underlying cause(s) of MSI and TMB in tumors remains poorly defined. We investigated associations of TMB to mismatch repair (MMR) protein expression patterns by immunohistochemistry (IHC) and MMR mutations in a diverse sample of tumors. Hypothesized differences were identified by the protein/gene affected/mutated and the tumor histology/primary site. Overall, 1057 MSI-H tumors were identified from the 32 932 tested. MSI was examined by NGS using 7000+ target microsatellite loci. TMB was calculated using only nonsynonymous missense mutations sequenced with a 592-gene panel; a subset of MSI-H tumors also had MMR IHC performed. Analyses examined TMB by MMR protein heterodimer impacted (loss of MLH1/PMS2 vs. MSH2/MSH6 expression) and gene-specific mutations. The sample was 54.6% female; mean age was 63.5 years. Among IHC tested tumors, loss of co-expression of MLH1/PMS2 was more common (n = 544/705, 77.2%) than loss of MSH2/MSH6 (n = 81/705, 11.5%; P < .0001), and was associated with lower mean TMB (MLH1/PMS2: 25.03 mut/Mb vs MSH2/MSH6 46.83 mut/Mb; P < .0001). TMB also varied by tumor histology: colorectal cancers demonstrating MLH1/PMS2 loss had higher TMBs (33.14 mut/Mb) than endometrial cancers (20.60 mut/Mb) and other tumors (25.59 mut/Mb; P < .0001). MMR gene mutations were detected in 42.0% of tumors; among these, MSH6 mutations were most common (25.7%). MSH6 mutation patterns showed variability by tumor histology and TMB. TMB varies by underlying cause(s) of MSI and tumor histology; this heterogeneity may contribute to differences in response to ICI. 相似文献
84.
85.
86.
87.
88.
89.
Kyung Won Lee Mi Sook Cho Dayeon Shin 《International journal of food sciences and nutrition》2016,67(2):184-194
Urinary iodine concentrations (UICs) in the US have been reported to be stable since 1988–1994, although those in selected subgroups remained low. We aimed to investigate iodine status among adults (≥20 years) by two different criteria of assessing iodine deficiency in population. Utilizing National Health and Nutrition Examination Surveys 2001–2012, we conducted linear logistic regressions adjusting for covariates. The prevalence of <50?μg/L UIC was higher in women than in men; increased from 11.6% (2001–2004) to 13.2% (2009–2012) at the national level and in young adults, non-Hispanic blacks (NHBs) and non-users of iodine-containing supplements (all, p?<0.05); the adjusted odds ratios (95%CI) in young adults (1.54 [1.11–2.15], p =?0.0007) and NHBs (1.70 [1.15–2.52], p =?0.0078). Median UICs confirm women and NHBs being in borderline iodine status. Recognizing the critical consequence of iodine deficiency particularly in women and NHBs, regular monitoring of iodine status is important for public health in the US. 相似文献